German research find way to specifically switch off autoimmunity


Essen – German researchers have found a way to turn immune effector cells – such as T-helper cells, which attack specific antigens on the surface of transplants – into immunosuppressive regulatory T-cells (Tregs) (J. Cell Mol.Med., doi: 10.111/j.1582-4934.2009.00782.x). The research group under Jan Buer from Essen University hospital succeeded in reprogramming T-effector cells into Tregs through overexpression of the newly discovered FoxP3 regulator GARP. In contrast, GARP inhibition in Tregs abolished their immunosuppressive effects. According to Buer, GARP is exclusively expressed in Tregs, and is the long-awaited marker that makes it possible to distiguish T-cell populations that carry the same surface antigens (CD4+ CD25+) but differ concerning the immunosuppressive phenotype. The discovery opens a way to switch off specific T-effector cell populations, a possible approach for treating autoimmune diseases.

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues